AERO-B03: A randomized phase II trial of dose-dense docetaxel in node-positive breast cancer

Journal of Clinical Oncology ◽

10.1200/jco.2005.23.16_suppl.647 ◽

2005 ◽

Vol 23 (16_suppl) ◽

pp. 647-647 ◽

Author(s):

P.-P. Piedbois ◽

D. Serin ◽

F. Priou ◽

P. Laplaige ◽

S. Greget ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Node Positive ◽

Randomized Phase Ii ◽

Positive Breast Cancer

Download Full-text

Dose-dense adjuvant chemotherapy in node-positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 randomized phase II study

Annals of Oncology ◽

10.1093/annonc/mdl355 ◽

2007 ◽

Vol 18 (1) ◽

pp. 52-57 ◽

Author(s):

P. Piedbois ◽

D. Serin ◽

F. Priou ◽

P. Laplaige ◽

S. Greget ◽

...

Keyword(s):

Breast Cancer ◽

Adjuvant Chemotherapy ◽

Phase Ii ◽

Phase Ii Study ◽

Node Positive ◽

Randomized Phase Ii ◽

Reverse Sequence ◽

Positive Breast Cancer

Download Full-text

Randomized Phase II Adjuvant Trial of Dose-Dense Docetaxel Before or After Doxorubicin Plus Cyclophosphamide in Axillary Node-Positive Breast Cancer

Breast Diseases A Year Book Quarterly ◽

10.1016/s1043-321x(09)79287-2 ◽

2009 ◽

Vol 20 (2) ◽

pp. 198-199

Author(s):

M.A. Tejani ◽

L.J. Goldstein

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Axillary Node ◽

Adjuvant Trial ◽

Node Positive ◽

Randomized Phase Ii ◽

Positive Breast Cancer

Download Full-text

Interim Results of BACH: Randomized Phase II Trial Evaluating the Safety of Two Chemotherapy Regimens as Adjuvant Therapy in Patients with HER2-Positive Breast Cancer: PLD + Cyclophosphamide + Trastuzumab (PLD+C+H), or Doxorubicin + Cyclophosphomide (A+C), Each Followed by Paclitaxel + Trastuzumab (T+H).

10.1158/0008-5472.sabcs-09-2085 ◽

2009 ◽

Author(s):

D. Rayson ◽

T. Suter ◽

S. van der Vegt ◽

C. Jackisch ◽

A. Lluch ◽

...

Keyword(s):

Breast Cancer ◽

Adjuvant Therapy ◽

Phase Ii ◽

Phase Ii Trial ◽

Her2 Positive ◽

Her2 Positive Breast Cancer ◽

Randomized Phase Ii ◽

Positive Breast Cancer

Download Full-text

Abstract P5-19-07: Randomized Phase II trial of afatinib alone or with vinorelbine versus investigator's choice of treatment in patients with HER2-positive breast cancer with progressive brain metastases after trastuzumab and/or lapatinib-based therapy: LUX-Breast 3

10.1158/1538-7445.sabcs14-p5-19-07 ◽

2015 ◽

Author(s):

Javier Cortés ◽

Veronique Dieras ◽

Jungsil Ro ◽

Jérôme Barriere ◽

Thomas Bachelot ◽

...

Keyword(s):

Breast Cancer ◽

Brain Metastases ◽

Phase Ii ◽

Phase Ii Trial ◽

Her2 Positive ◽

Her2 Positive Breast Cancer ◽

Randomized Phase Ii ◽

Choice Of Treatment ◽

Positive Breast Cancer

Download Full-text

5149 Randomized phase II trial of preoperative chemotherapy plus lapatinib, trastuzumab or both in HER2 positive breast cancer: results of the first step simon's design

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(09)71041-9 ◽

2009 ◽

Vol 7 (2) ◽

pp. 304

Author(s):

V. Guarneri ◽

A. Frassoldati ◽

A. Bottini ◽

K. Cagossi ◽

L. Cavanna ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Preoperative Chemotherapy ◽

Phase Ii Trial ◽

Her2 Positive ◽

Her2 Positive Breast Cancer ◽

Randomized Phase Ii ◽

Positive Breast Cancer

Download Full-text

A randomised feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancer

Acta Oncologica ◽

10.3109/0284186x.2010.535847 ◽

2010 ◽

Vol 50 (1) ◽

pp. 35-41 ◽

Author(s):

Sara Margolin ◽

Nils-Olof Bengtsson ◽

Lena Carlsson ◽

Per Edlund ◽

Mats Hellstrøm ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Node Positive ◽

Positive Breast Cancer

Download Full-text

A randomized feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancer

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(08)70548-2 ◽

2008 ◽

Vol 6 (7) ◽

pp. 116-117

Author(s):

S. Margolin ◽

L. Carlsson ◽

M. Hellstrom ◽

P. Karlsson ◽

E. Lidbrink ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Node Positive ◽

Positive Breast Cancer

Download Full-text

Phase II Study of Feasibility of Dose-Dense FEC Followed by Alternating Weekly Taxanes in High-Risk, Four or More Node-Positive Breast Cancer

Breast Diseases A Year Book Quarterly ◽

10.1016/s1043-321x(05)80227-9 ◽

2005 ◽

Vol 16 (3) ◽

pp. 278

Author(s):

D. Shafer ◽

L.J. Goldstein

Keyword(s):

Breast Cancer ◽

High Risk ◽

Phase Ii ◽

Phase Ii Study ◽

Node Positive ◽

Positive Breast Cancer

Download Full-text

Ki-67 Index Guided Selection of Preoperative Chemotherapy for HER2-positive Breast Cancer: A Randomized Phase II Trial

Japanese Journal of Clinical Oncology ◽

10.1093/jjco/hys161 ◽

2012 ◽

Vol 42 (12) ◽

pp. 1211-1214 ◽

Author(s):

T. Yamaguchi ◽

H. Mukai

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Preoperative Chemotherapy ◽

Phase Ii Trial ◽

Her2 Positive ◽

Ki 67 ◽

Her2 Positive Breast Cancer ◽

Randomized Phase Ii ◽

Selection Of ◽

Positive Breast Cancer

Download Full-text

Use of the neo-adjuvant exemestane in post-menopausal estrogen receptor-positive breast cancer: A randomized phase II trial (PTEX46) to investigate the optimal duration of preoperative endocrine therapy

10.1016/j.breast.2013.03.002 ◽

2013 ◽

Vol 22 (3) ◽

pp. 263-267 ◽

Author(s):

Takashi Hojo ◽

Takayuki Kinoshita ◽

Shigeru Imoto ◽

Chikako Shimizu ◽

Hirotsugu Isaka ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Endocrine Therapy ◽

Phase Ii ◽

Phase Ii Trial ◽

Randomized Phase Ii ◽

Optimal Duration ◽

Estrogen Receptor Positive ◽

Post Menopausal ◽

Positive Breast Cancer

Download Full-text